Description
Peptide T is an octapeptide fragment of the V2 region of HIV-1 glycoprotein gp120. Peptide T exhibits anti-inflammatory activity, decreasing inflammation and acting as a potential treatment for psoriasis. Peptide T also inhibits HIV entry, blocking binding and infection of HIV strains that require CCR5 for entry. Peptide T also displays some neuroprotective activity, improving cognitive performance in neuroAIDS subjects.
References
Paoletti I, De Gregorio V, Baroni A, et al. Amygdalin analogues inhibit IFN-γ signalling and reduce the inflammatory response in human epidermal keratinocytes. Inflammation. 2013 Dec;36(6):1316-26. PMID: 23933845.
D'ursi A, Caliendo G, Perissutti E, et al. Conformation-activity relationship of peptide T and new pseudocyclic hexapeptide analogs. J Pept Sci. 2007 Jun;13(6):413-21. PMID: 17486694.
Polianova MT, Ruscetti FW, Pert CB, et al. Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA). Antiviral Res. 2005 Aug;67(2):83-92. PMID: 16002156.
Ruff MR, Melendez-Guerrero LM, Yang QE, et al. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 2001 Oct;52(1):63-75. PMID: 11530189.
Heseltine PN, Goodkin K, Atkinson JH, et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol. 1998 Jan;55(1):41-51. PMID: 9443710.